Omeros

Omeros, founded in 1994 and headquartered in Seattle, WA on Elliott Bay in Lower Queen Anne, is a publicly traded biopharmaceutical company listed on NASDAQ under the ticker symbol OMER. The company employs over 200 people and is dedicated to addressing significant unmet medical needs through the development of first-in-class drugs. Omeros has a deep and diverse pipeline of small-molecule and protein therapeutics, retaining exclusive control of worldwide commercial rights for all its products, product candidates, and programs.

The company leverages proprietary technologies, including GPCR deorphanization and a cellular redistribution assay (CRA) for high-throughput identification of synthetic ligands for orphan GPCRs. Omeros has identified and confirmed sets of compounds that interact selectively with various orphan receptors and has a proprietary ex vivo platform for discovering novel, high-affinity monoclonal antibodies.

Omeros is advancing research and development programs targeting both orphan and large-market indications. Key projects include the evaluation of narsoplimab (OMS721) in lectin pathway-mediated diseases such as stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and the study of OMS906 in alternative pathway-mediated diseases like paroxysmal nocturnal hemoglobinuria (PNH) and complement 3 glomerulopathy (C3G). The company collaborates with the University of Cambridge to establish the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR).

The company’s PDE7 inhibitor OMS527 has shown promise in reducing craving and relapse in animal models of various addictions and binge eating. Omeros is also developing novel immunotherapeutics to harness the body’s immune system to fight cancer and has initiated programs to target globally immunosuppressive signaling in T cells. Their proprietary technology combines inhibitors of GPR174, adenosine A2, and potentially other targets to limit the negative impact of immunosuppressive signaling on T cell function.

Omeros’ pipeline includes narsoplimab (OMS721), OMS405, OMS527, OMS906, OMS1029, MASP-2, MASP-3, MASP-2/-3, GPR174, and Adoptive T Cell Therapies/CAR T. The company has received a $6.69 million grant from the National Institute on Drug Abuse to support studies on OMS527 for cocaine use disorder and has received orphan drug designation from the FDA for OMS906 for the treatment of PNH. Additionally, Omeros has initiated a Phase 1 clinical trial to evaluate the safety and tolerability of OMS1029 in healthy subjects and is developing orally available small-molecule inhibitors of MASP-2, MASP-3, and bispecific inhibitors of MASP-2/-3.